A 2026 prospective German aneurysm cohort found risky alcohol use in 4.6% of 954 intracranial aneurysm patients, and that exposure carried 2.00x higher adjusted odds of aneurysm rupture plus 3.26x higher adjusted odds of clinically severe aneurysmal subarachnoid hemorrhage. Research Highlights Risky alcohol was the main signal: drinking above the study threshold was independently associated …
A 2026 Taiwanese case series reported VAS pain drops in all 3 adults treated with pregabalin for type I complex regional pain syndrome: 9 to 5, 2 to 1, and 6 to 3 after doses of 75-150 mg/day. The signal is clinically interesting because pain relief helped rehabilitation participation, but the evidence remains weak because …
A 2026 case series of 10 adults with refractory postherpetic neuralgia found: 3 of 8 patients responded to a spinal cord stimulation trial, 2 kept meaningful 24-month relief after implantation, and 3 dorsal root entry zone lesioning cases reported 60-90% pain relief at 24 months.1 The data are too small to rank the procedures, but …
A 2026 iScience study found that adults could learn a new auditory cue to visual depth after about 1 hour, but full perceptual integration did not appear reliably at the group level: only 31 of 63 participants, or 49%, gained precision when the novel cue was combined with familiar visual disparity.1 The sharp interpretation separates …
A 745-child cohort found positive MCHAT-R/F autism screens in 22 of 218 children exposed to maternal SARS-CoV-2 infection during pregnancy (10.1%) vs. 30 of 527 pre-pandemic controls (5.7%; p = 0.03).1 The same 2026 analysis added a small serum-proteomics layer: exposed newborns who later screened positive showed altered immune and metabolic markers, but the paper …
A 2026 exploratory analysis of the ABCD cancer dyspnea trial found that higher baseline cytokines predicted less placebo symptom improvement than lower baseline cytokines across 33 of 40 cytokine-symptom combinations at day 7 and 29 of 40 at day 14.1 The signal is not ready for clinical prediction, but it sharpens a trial-design problem: patients …
A 2026 immunopsychiatry cohort study found that soluble CD27 (sCD27), a marker of T-cell activation, was positive in cerebrospinal fluid in 23% of severe psychiatric patients selected for suspected immune involvement and in 88% of multiple sclerosis patients used as a positive-control group. In the psychiatric cohort, combined cerebrospinal fluid or blood sCD27 positivity was …